tradingkey.logo

Oncology Institute Inc

TOI
2.610USD
+0.160+6.53%
Handelsschluss 02/06, 16:00ETKurse um 15 Minuten verzögert
254.66MMarktkapitalisierung
VerlustKGV TTM

Oncology Institute Inc

2.610
+0.160+6.53%

mehr Informationen über Oncology Institute Inc Unternehmen

The Oncology Institute, Inc. is a value-based oncology company. The Company manages community-based oncology practices which serve patients at approximately 86 clinic locations across 16 markets and five states throughout the United States. The Company's segment includes patient services, dispensary, and clinical trials & other. Its managed clinics provide a range of medical oncology services, including physician services, in-house infusion, radiation, and programs like outpatient blood product transfusions, along with 24/7 patient support. The Company, through TOI Clinical Research, LLC (TCR), provides and manages clinical trial services and research for the benefit of cancer patients. The Company also provides management services to over 14 clinic locations owned by independent oncology practices. The Company and its affiliated providers have contractual relationships with payors serving a variety of patients, including Medicare Advantage (MA), Medicaid, and commercial patients.

Oncology Institute Inc Informationen

BörsenkürzelTOI
Name des UnternehmensOncology Institute Inc
IPO-datumMar 13, 2020
CEOVirnich (Daniel)
Anzahl der mitarbeiter825
WertpapierartOrdinary Share
GeschäftsjahresendeMar 13
Addresse18000 Studebaker Rd
StadtCERRITOS
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl90703
Telefon15627353226
Websitehttps://theoncologyinstitute.com/
BörsenkürzelTOI
IPO-datumMar 13, 2020
CEOVirnich (Daniel)

Führungskräfte von Oncology Institute Inc

Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Daniel Virnich, M.D.
Dr. Daniel Virnich, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.20M
+12675.00%
Dr. Mohit Kaushal
Dr. Mohit Kaushal
Independent Director
Independent Director
289.09K
+91049.00%
Mr. Robert Ross Carter
Mr. Robert Ross Carter
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
235.13K
-244.00%
Dr. Yale Podnos
Dr. Yale Podnos
Chief Medical Officer
Chief Medical Officer
196.63K
+3594.00%
Ms. Kristin England
Ms. Kristin England
Chief Administrative Officer
Chief Administrative Officer
98.04K
+98037.00%
Mr. Mark L. Pacala
Mr. Mark L. Pacala
Independent Director
Independent Director
--
--
Mr. Brad Hively
Mr. Brad Hively
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
Ms. Karen M. Johnson
Ms. Karen M. Johnson
Independent Director
Independent Director
--
--
Ms. Anne Mcgeorge
Ms. Anne Mcgeorge
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Daniel Virnich, M.D.
Dr. Daniel Virnich, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.20M
+12675.00%
Dr. Mohit Kaushal
Dr. Mohit Kaushal
Independent Director
Independent Director
289.09K
+91049.00%
Mr. Robert Ross Carter
Mr. Robert Ross Carter
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
235.13K
-244.00%
Dr. Yale Podnos
Dr. Yale Podnos
Chief Medical Officer
Chief Medical Officer
196.63K
+3594.00%
Ms. Kristin England
Ms. Kristin England
Chief Administrative Officer
Chief Administrative Officer
98.04K
+98037.00%
Mr. Mark L. Pacala
Mr. Mark L. Pacala
Independent Director
Independent Director
--
--

Umsatzaufteilung

Währung: USDAktualisiert: Tue, Jan 6
Währung: USDAktualisiert: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Dispensary revenue
75.89M
55.57%
FFS revenue
39.62M
29.01%
Capitated revenue
20.57M
15.07%
Clinical research trials and other revenue
474.00K
0.35%
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Dispensary revenue
75.89M
55.57%
FFS revenue
39.62M
29.01%
Capitated revenue
20.57M
15.07%
Clinical research trials and other revenue
474.00K
0.35%

Aktionärsstatistik

Aktualisiert: Wed, Feb 4
Aktualisiert: Wed, Feb 4
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
M33 Growth LLC
5.53%
Chernett (Jorey)
5.20%
The Vanguard Group, Inc.
4.83%
OncologyCare Partners LLC
4.18%
Deerfield Management Company, L.P.
3.42%
Andere
76.85%
Aktionäre
Aktionäre
Anteil
M33 Growth LLC
5.53%
Chernett (Jorey)
5.20%
The Vanguard Group, Inc.
4.83%
OncologyCare Partners LLC
4.18%
Deerfield Management Company, L.P.
3.42%
Andere
76.85%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
12.45%
Hedge Fund
11.07%
Investment Advisor/Hedge Fund
10.11%
Individual Investor
10.09%
Venture Capital
5.53%
Corporation
4.18%
Research Firm
0.92%
Private Equity
0.26%
Bank and Trust
0.17%
Andere
45.22%

Institutionelle Beteiligung

Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
172
39.71M
40.37%
-15.56M
2025Q3
145
39.72M
42.48%
-7.79M
2025Q2
119
39.72M
44.51%
-19.63M
2025Q1
137
46.36M
52.04%
-13.47M
2024Q4
138
45.05M
59.62%
-19.81M
2024Q3
139
50.89M
67.39%
-11.59M
2024Q2
143
57.80M
76.77%
-3.05M
2024Q1
146
56.10M
75.87%
-3.90M
2023Q4
143
57.48M
77.79%
-4.30M
2023Q3
176
58.70M
79.97%
-14.73M
Mehr Anzeigen

Aktionärsaktivitäten

Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
M33 Growth LLC
5.44M
5.53%
-3.08M
-36.13%
Nov 18, 2025
The Vanguard Group, Inc.
4.55M
4.62%
+264.36K
+6.18%
Sep 30, 2025
OncologyCare Partners LLC
4.11M
4.18%
--
--
Mar 26, 2025
Deerfield Management Company, L.P.
3.36M
3.42%
--
--
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
3.12M
3.17%
+119.92K
+4.00%
Sep 30, 2025
CenterBook Partners LP
2.70M
2.75%
+1.99M
+277.80%
Sep 30, 2025
Balyasny Asset Management LP
2.52M
2.56%
--
--
Sep 30, 2025
Kanen Wealth Management, LLC
1.84M
1.87%
+1.84M
--
Sep 30, 2025
Wexford Capital LP
1.57M
1.6%
+452.39K
+40.44%
Sep 30, 2025
Mehr Anzeigen

Verbundene ETFs

Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
Vanguard US Momentum Factor ETF
0.11%
iShares Micro-Cap ETF
0.05%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.03%
Global X Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares UltraPro Russell2000
0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
0.01%
iShares Russell 2000 Growth ETF
0.01%
Vanguard US Momentum Factor ETF
Anteil0.11%
iShares Micro-Cap ETF
Anteil0.05%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Anteil0.03%
Global X Russell 2000 ETF
Anteil0.01%
ProShares Hedge Replication ETF
Anteil0.01%
iShares Russell 2000 ETF
Anteil0.01%
Proshares Ultra Russell 2000
Anteil0.01%
ProShares UltraPro Russell2000
Anteil0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
Anteil0.01%
iShares Russell 2000 Growth ETF
Anteil0.01%

Dividende

In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten

Aktien-Split

Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
KeyAI